Lonza Group AG (LONN) - Total Liabilities
Based on the latest financial reports, Lonza Group AG (LONN) has total liabilities worth CHF9.78 Billion CHF as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lonza Group AG - Total Liabilities Trend (2004–2025)
This chart illustrates how Lonza Group AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lonza Group AG Competitors by Total Liabilities
The table below lists competitors of Lonza Group AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHINA PAC.IN.GR.GDR/5 YC1
F:75CB
|
Germany | €2.81 Trillion |
|
ASM INTL N.V. NY/1 EO-04
F:AVSN
|
Germany | €1.33 Billion |
|
Martin Marietta Materials Inc
NYSE:MLM
|
USA | $8.68 Billion |
|
Prudential Financial Inc
NYSE:PRU
|
USA | $738.16 Billion |
|
OTP Bank Nyrt
BUD:OTP
|
Hungary | Ft39.10 Trillion |
|
Beijing-Shanghai High Speed Railway Co Ltd
SHG:601816
|
China | CN¥60.41 Billion |
|
Shaanxi Coal Industry Co Ltd
SHG:601225
|
China | CN¥100.49 Billion |
|
Baidu Inc
NASDAQ:BIDU
|
USA | $159.43 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Lonza Group AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lonza Group AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lonza Group AG (2004–2025)
The table below shows the annual total liabilities of Lonza Group AG from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF9.78 Billion | -5.46% |
| 2024-12-31 | CHF10.35 Billion | +41.02% |
| 2023-12-31 | CHF7.34 Billion | +9.64% |
| 2022-12-31 | CHF6.69 Billion | +0.83% |
| 2021-12-31 | CHF6.64 Billion | -14.27% |
| 2020-12-31 | CHF7.74 Billion | +6.39% |
| 2019-12-31 | CHF7.28 Billion | -4.65% |
| 2018-12-31 | CHF7.63 Billion | -0.25% |
| 2017-12-31 | CHF7.65 Billion | +71.03% |
| 2016-12-31 | CHF4.47 Billion | +8.75% |
| 2015-12-31 | CHF4.11 Billion | -4.59% |
| 2014-12-31 | CHF4.31 Billion | +1.51% |
| 2013-12-31 | CHF4.25 Billion | -9.52% |
| 2012-12-31 | CHF4.69 Billion | +0.64% |
| 2011-12-31 | CHF4.66 Billion | +95.06% |
| 2010-12-31 | CHF2.39 Billion | -6.42% |
| 2009-12-31 | CHF2.56 Billion | -18.71% |
| 2008-12-31 | CHF3.14 Billion | 0.00% |
| 2007-12-31 | CHF3.14 Billion | +36.36% |
| 2006-12-31 | CHF2.31 Billion | -18.87% |
| 2005-12-31 | CHF2.84 Billion | +38.18% |
| 2004-12-31 | CHF2.06 Billion | -- |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more